Company intelligence / Profile preview

Absea Biotechnology

Berlin, Berlin, Germanyde.linkedin.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Absea has developed a high-throughput platform for producing soluble proteins and monoclonal antibodies at scale. The company claims over 14,000 recombinant proteins and more than 13,000 monoclonal antibodies produced to date. Their products are validated for diverse applications in proteomics, interactomics, diagnostics, and drug discovery support. No direct clinical results as they do not develop therapeutics themselves.

Therapeutic areas: Other
Modalities: Recombinant proteinMonoclonal antibody
Industry: Non-Drug Biotech

Partnerships

Collaborates with leaders in life sciences including AI-driven protein design companies and diagnostic/drug development partners; specific names not disclosed.

Beyond the preview

Go deeper on Absea Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Absea Biotechnology.

Explore the full profile